Core Insights - Cardio Diagnostics Holdings, Inc. will host an investor conference call on February 18, 2026, at 3 p.m. Central Time to discuss its precision molecular approach to cardiovascular disease prevention and early detection [1] - The call will cover updates on commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent clinical data, reimbursement progress, and strategic growth initiatives [1] Company Overview - Cardio Diagnostics is a precision cardiovascular medicine company utilizing epigenetics, genetics, and artificial intelligence to enhance the prevention and detection of cardiovascular disease [1] - The company aims to make cardiovascular disease management more accessible, personalized, and precise through its proprietary AI-driven Integrated Genetic-Epigenetic Engine [1] Financial and Operational Updates - The Centers for Medicare and Medicaid Services (CMS) has issued a final gapfill payment rate of $854 for both the Epi+Gen CHD™ and PrecisionCHD™ tests [1] - The company is actively pursuing strategic partnerships, including a recent collaboration with Aimil Ltd. and Dr. Lal PathLabs to launch the PrecisionCHD™ test in India [1]

Core Insights - Edwards Lifesciences will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, with CFO Scott Ullem scheduled to speak at 9:50 a.m. ET [1] - The company announced that the U.S. District Court has granted the FTC's motion to block its proposed acquisition of JenaValve Technology, which Edwards believes would have benefited a significant patient population [1] - The FDA has approved Edwards Lifesciences' SAPIEN M3 mitral valve replacement system as the first transcatheter therapy using a transseptal approach for treating mitral regurgitation [1] Company Participation in Conferences - Edwards Lifesciences will participate in the J.P. Morgan Healthcare Conference on January 12, 2026, with CEO Bernard Zovighian and CFO Scott Ullem scheduled to present [1] Product Approvals and Innovations - The SAPIEN M3 mitral valve replacement system is indicated for symptomatic moderate-to-severe or severe mitral regurgitation in patients deemed unsuitable for surgery, marking a significant advancement in transcatheter therapies [1]

Core Insights - Vasomune Therapeutics Inc. and AnGes Inc. have expanded their co-development agreement to include additional indications for the Tie2 receptor agonist Pegevongitide (AV-001) [1][2] - The expanded research will explore Pegevongitide's potential in treating conditions beyond Acute Respiratory Distress Syndrome, including cognitive impairment associated with hemodialysis [2] Company Overview - Vasomune Therapeutics is a private clinical-stage biopharmaceutical company founded in 2014, focusing on developing medicines to enhance the body's defense against vascular leak [4] - The company has advanced Pegevongitide (AV-001) from preclinical stages to clinical trials, targeting various diseases linked to vascular dysfunction [4] - AnGes Inc., established in December 1999, specializes in gene-based medicines and is developing AV-001 for pneumonia and other conditions [6] Financial and Developmental Aspects - The expanded agreement provides Vasomune with increased financial support and opportunities to pursue further development to address pathological vascular leakage [3]

Core Insights - Cardio Diagnostics Holdings, Inc. partners with YMCA of East Tennessee to provide heart health education and advanced testing to the community [1][4] - The initiative aims to empower individuals to take proactive steps in cardiovascular wellness through education and early detection tools [2][4] Partnership Details - The program includes "Wisdom Wednesdays," an educational series for YMCA members, and access to discounted AI-powered cardiovascular tests [1][5] - Cardio Diagnostics will offer Epi+Gen CHD and PrecisionCHD tests at special rates, which assess the risk of coronary heart disease and aid in its management [6][8] Community Impact - Heart disease is the leading cause of death in Tennessee, accounting for 22.9% of all deaths, highlighting the need for preventive measures [2] - The YMCA serves over 40,000 members across five locations, emphasizing its role in promoting health and wellness in the Knoxville community [3] Educational Initiatives - Six educational sessions will be held starting in November 2025, focusing on coronary heart disease prevention and management [5] - The first session will feature Cardio Diagnostics' Chief Medical Officer discussing the importance of heart health [5] Testing Accessibility - Community members can access tests through telemedicine, with options for at-home sample collection or at the Heart Health Fair in February 2026 [6][7] - The partnership aims to extend access to cardiovascular testing beyond YMCA members to the entire East Tennessee community [8]